- Home
- SNGX vs MBIO Comparison
SNGX vs MBIO Comparison
Compare SNGX & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- MBIO
- Stock Information
- Founded
- SNGX 1987
- MBIO 2015
- Country
- SNGX United States
- MBIO United States
- Employees
- SNGX N/A
- MBIO N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- MBIO Health Care
- Exchange
- SNGX Nasdaq
- MBIO Nasdaq
- Market Cap
- SNGX 9.6M
- MBIO 9.1M
- IPO Year
- SNGX 1987
- MBIO N/A
- Fundamental
- Price
- SNGX $3.16
- MBIO $0.17
- Analyst Decision
- SNGX
- MBIO Strong Buy
- Analyst Count
- SNGX 0
- MBIO 1
- Target Price
- SNGX N/A
- MBIO $2.00
- AVG Volume (30 Days)
- SNGX 46.1K
- MBIO 607.5K
- Earning Date
- SNGX 11-08-2024
- MBIO 11-08-2024
- Dividend Yield
- SNGX N/A
- MBIO N/A
- EPS Growth
- SNGX N/A
- MBIO N/A
- EPS
- SNGX N/A
- MBIO N/A
- Revenue
- SNGX $364,183.00
- MBIO N/A
- Revenue This Year
- SNGX N/A
- MBIO N/A
- Revenue Next Year
- SNGX $76.64
- MBIO N/A
- P/E Ratio
- SNGX N/A
- MBIO N/A
- Revenue Growth
- SNGX N/A
- MBIO N/A
- 52 Week Low
- SNGX $1.83
- MBIO $0.13
- 52 Week High
- SNGX $19.20
- MBIO $1.53
- Technical
- Relative Strength Index (RSI)
- SNGX 41.70
- MBIO 32.12
- Support Level
- SNGX $2.93
- MBIO $0.16
- Resistance Level
- SNGX $3.35
- MBIO $0.21
- Average True Range (ATR)
- SNGX 0.19
- MBIO 0.02
- MACD
- SNGX -0.01
- MBIO -0.00
- Stochastic Oscillator
- SNGX 37.10
- MBIO 18.17
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.